Evotec Stock - Insider sale by CSO Dohrmann draws market attention
Published on 06/17/2026 at 18:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 18:49 CET. Details in the imprint.
Evotec (DE0005664809) has come under renewed scrutiny this week after a sizeable insider transaction by Chief Scientific Officer Dr. Cord Dohrmann was disclosed. According to a BaFin directors' dealing notice and a related Form 6-K filing, the long-serving executive sold a substantial block of shares. The EQS-DD disclosure filed via Deutsche Börse
All news and background on Evotec stock
Further corporate news, regulatory disclosures and price data on Evotec stock can be found in the dedicated topic section and on the company's investor-relations pages.
What the insider filing shows
The directors' dealing notice states that on 06/15/2026 Dr. Cord Dohrmann sold 119,900 Evotec shares at a price of EUR 4.81 each, for an aggregated volume of EUR 576,720.00. The EQS-DD notice via Deutsche Börse
German financial portal reports add that BaFin published the managers' transaction on 06/16/2026, with Evotec shares closing that day at around EUR 4.66 on the Frankfurt Stock Exchange, down roughly 3.1% from the prior session. Coverage of the BaFin transaction notice on finanzen.net
Operations and strategy on Wednesday
Beyond the insider dealing, Evotec continues to position itself as a drug discovery and development partner with a focus on an "asset-light" model and partnering revenues. Recent strategy materials highlight operational excellence, pipeline growth and long-term collaborations with big pharma clients. A recent strategy presentation summary
In this model, Evotec invests in platforms and early-stage assets while sharing development risk and upside with partners, aiming for recurring service revenue and potential milestones and royalties over time.
How the company makes money
Evotec's core business is providing discovery and development services, including integrated research programs and platform-based offerings in areas such as neuroscience, metabolic diseases and oncology. The company generates revenue from research fees, milestones and, in some cases, future royalty streams.
Where the stock trades today
The shares of Evotec (DE0005664809) trade on Xetra at EUR 4.58 as of 06/17/2026, 17:30 CET.
Key facts on Evotec stock
- Company: Evotec SE
- ISIN: DE0005664809
- WKN: 566480
- Ticker: EVT
- Venue: Xetra
- Price (as of 06/17/2026, 17:30 CET): 4.58 EUR
- Market cap: 1,570,000,000 EUR (as of 06/17/2026)
- Sector / Industry: Health Care - Biotechnology
- Index membership: MDAX
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
